Contrasting Revvity (RVTY) and Its Rivals

Revvity (NYSE:RVTY – Get Rating) is one of 44 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Revvity to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Earnings & Valuation

This table compares Revvity and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Revvity	$3.31 billion	$569.18 million	15.66
Revvity Competitors	$1.13 billion	-$234.91 million	-33.42

Revvity has higher revenue and earnings than its competitors. Revvity is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Dividends

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Revvity pays out 3.6% of its earnings in the form of a dividend. As a group, “Analytical instruments” companies pay a dividend yield of 0.4% and pay out 9.7% of their earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Revvity and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0	0	1	0	3.00
Revvity Competitors	196	1120	1724	62	2.53

As a group, “Analytical instruments” companies have a potential upside of 24.31%. Given Revvity’s competitors higher probable upside, analysts plainly believe Revvity has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

85.2% of Revvity shares are owned by institutional investors. Comparatively, 56.5% of shares of all “Analytical instruments” companies are owned by institutional investors. 0.5% of Revvity shares are owned by company insiders. Comparatively, 16.5% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Revvity has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Revvity’s competitors have a beta of 1.03, indicating that their average stock price is 3% more volatile than the S&P 500.

Profitability

This table compares Revvity and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revvity	28.94%	11.17%	5.83%
Revvity Competitors	-298.81%	-224.27%	-17.24%

Summary

Revvity beats its competitors on 11 of the 15 factors compared.

Revvity Company Profile

(Get Rating)

Revvity, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.